Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06974175

Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation

Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation. Pilot Study

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
Sex
Male
Age
20 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Male Accessory Glands Inflammations (MAGI) include inflammatory diseases involving seminal vescicles and the prostate. Patients suffering from them present an impaired fertility because of seminal duct obstruction and alterations of the rheologic and functional parameters of semen, induced by direct microbiological action as well as inflammatory and oxidative damage. Inflammation in seminal plasma can be detected and measured by dosing of inflammatory molecules such as SuPAR and ST2. Treatment of MAGIs include specific antibiotic therapy in addition to use of anti-inflammatory nutraceutics. Deprox HP is a nutraceutic containing GraminexTM, a compound made of pollen extracts of rye, mais and timothy. To investigate its efficacy, we evalued seminal parameters, inflammatory and oxidative molecules in seminal plasma and clinical and ultrasonographic features of male accessory glands before and after 3 months of treatment in 20 patients taking Deprox HP and 20 patients undergoing treatment with palmitoilethanolammide, bromelin and horse chestnut extract.

Conditions

Interventions

TypeNameDescription
OTHERDeprox_HPUse of nutraceutic based on a compound of pollen extracts from pollen, mais and timothy
OTHERPeacistUse of a nutraceutic based on palmitoilethanolamide + Bromelin + Horse Chestunt extract

Timeline

Start date
2025-09-01
Primary completion
2026-03-30
Completion
2026-05-01
First posted
2025-05-15
Last updated
2025-08-14

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06974175. Inclusion in this directory is not an endorsement.